tetano
Editor, Senior Moderator
Health Sci Rep
. 2024 Feb 7;7(2):e1871.
doi: 10.1002/hsr2.1871. eCollection 2024 Feb. Economic evaluation of vaccination against COVID-19: A systematic review
Dolatshahi Zeinab[SUP] 1 [/SUP], Nargesi Shahin[SUP] 2 [/SUP], Mezginejad Fateme[SUP] 3 [/SUP], Bagheri Faradonbeh Saeed[SUP] 4 [/SUP]
Affiliations
Background and aims: Coronavirus has burdened considerable expenditures on the different health systems. Vaccination programs, the critical solution against pandemic diseases, are known as safe and effective interventions to prevent and control epidemics. We aimed to perform a systematic review to provide economic evidence of the value of different types of vaccines available to combat the Covid-19 to all health policymakers worldwide.
Methods: Electronic searches conducted on Medline/PubMed, Cochrane Library, Web of Science, Scopus, Embase, and other economic evaluation databases. Related and published articles searched up to March 2022 by using keywords such as "Vaccination," "Covid-19," "Cost-benefit," "Cost-utility," "Cost-effectiveness," "Economic Assessment," and "Economic evaluation." Followed by choosing the most suitable articles according to inclusion and exclusion criteria, data captured and the results extracted. The quality assessment of the articles performed by the checklist of CHEERS 2022. Finally, 13 articles included in the review.
Results: All messenger RNA vaccines were dominant with approximately 70% coverage against no vaccination in the primary vaccination program except in one study that looked at booster effects. From a payer's perspective, a dollar invested in a vaccine would be less profitable than from a societal perspective. Therefore, primary mass vaccination can be considered a cost-effective intervention in primary vaccination to save more lives and produce more positive externalities. However, the cost-benefit ratio for all vaccines increases when statistical lifetime value and global economic and educational disadvantages are considered.
Conclusion: The COVID-19 primary vaccination programs in regional outbreaks, from a long-term perspective, will demonstrate substantial cost-effectiveness. It is suggested that due to the positive externalities of vaccination, primary mass vaccination, with the help of COVAX-19TM, could be considered a reliable way to combat viral epidemics compared to the loss of individual lives and economic and educational disturbances around the world.
Keywords: COVID‐19; cost‐benefit analysis; cost‐effectiveness analysis; cost‐utility analysis; vaccine.
. 2024 Feb 7;7(2):e1871.
doi: 10.1002/hsr2.1871. eCollection 2024 Feb. Economic evaluation of vaccination against COVID-19: A systematic review
Dolatshahi Zeinab[SUP] 1 [/SUP], Nargesi Shahin[SUP] 2 [/SUP], Mezginejad Fateme[SUP] 3 [/SUP], Bagheri Faradonbeh Saeed[SUP] 4 [/SUP]
Affiliations
- PMID: 38332928
- PMCID: PMC10850437
- DOI: 10.1002/hsr2.1871
Background and aims: Coronavirus has burdened considerable expenditures on the different health systems. Vaccination programs, the critical solution against pandemic diseases, are known as safe and effective interventions to prevent and control epidemics. We aimed to perform a systematic review to provide economic evidence of the value of different types of vaccines available to combat the Covid-19 to all health policymakers worldwide.
Methods: Electronic searches conducted on Medline/PubMed, Cochrane Library, Web of Science, Scopus, Embase, and other economic evaluation databases. Related and published articles searched up to March 2022 by using keywords such as "Vaccination," "Covid-19," "Cost-benefit," "Cost-utility," "Cost-effectiveness," "Economic Assessment," and "Economic evaluation." Followed by choosing the most suitable articles according to inclusion and exclusion criteria, data captured and the results extracted. The quality assessment of the articles performed by the checklist of CHEERS 2022. Finally, 13 articles included in the review.
Results: All messenger RNA vaccines were dominant with approximately 70% coverage against no vaccination in the primary vaccination program except in one study that looked at booster effects. From a payer's perspective, a dollar invested in a vaccine would be less profitable than from a societal perspective. Therefore, primary mass vaccination can be considered a cost-effective intervention in primary vaccination to save more lives and produce more positive externalities. However, the cost-benefit ratio for all vaccines increases when statistical lifetime value and global economic and educational disadvantages are considered.
Conclusion: The COVID-19 primary vaccination programs in regional outbreaks, from a long-term perspective, will demonstrate substantial cost-effectiveness. It is suggested that due to the positive externalities of vaccination, primary mass vaccination, with the help of COVAX-19TM, could be considered a reliable way to combat viral epidemics compared to the loss of individual lives and economic and educational disturbances around the world.
Keywords: COVID‐19; cost‐benefit analysis; cost‐effectiveness analysis; cost‐utility analysis; vaccine.